Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a clinical-stage precision medicine oncology company focused on discovering and developing targeted small-molecule therapies for biomarker-defined cancers. The company’s core scientific approach is synthetic lethality, aiming to exploit cancer-specific genetic vulnerabilities to improve tumor killing while limiting harm to healthy tissue. Its pipeline has evolved from earlier mutant p53 programs toward DNA damage response, or DDR, pathway targets acquired and advanced after the Atrin transaction in 2022. Aprea remains pre-commercial and is funded primarily through equity financing and grants rather than product sales.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSmall-molecule drug candidates being advanced through preclinical, IND-enabling, and clinical development for biomarker-defined cancers.
Programs targeting ATR, WEE1, and related DDR pathways intended to create synthetic lethality in tumor cells.
Earlier-stage research assets, including undisclosed DDR targets and next-generation oncology molecules.
Non-product funding and scientific support, including grant-backed combination studies and potential partnering.
Customers
Aprea does not currently sell commercial products, so its near-term counterparties are primarily research funders, clinical investigators, and potential licensing or collaboration partners rather than end-market patients. The company’s eventual customers would be oncology physicians and hospitals treating biomarker-defined cancer patients if any candidate reaches approval. In the development phase, the company also relies on contract manufacturers, CROs, and academic or government research collaborators to advance its pipeline. Because the business is pre-revenue, partner interest in the science and clinical data is central to future monetization.
Cancer centers and oncologists would use approved therapies for patients whose tumors match the relevant genetic biomarkers.
Patients with DDR-related or other genetically defined tumors are the intended end users of the company’s precision oncology drugs.
Larger biopharma companies may license or co-develop assets to gain access to Aprea’s synthetic lethality programs.
Public funding bodies such as the National Cancer Institute support selected preclinical and combination studies.
Specialist vendors provide API, drug product, and clinical supply services needed to advance candidates.
Strategy
Aprea’s strategy is to advance a focused pipeline of synthetic lethality oncology assets that target DDR pathways and biomarker-defined tumors. The company is prioritizing ATRN-119 and APR-1051 while also keeping earlier-stage programs such as APR-1602 and an undisclosed DDR target moving toward IND-enabling work. Combination strategies, including pairing with PARP inhibitors and other agents, are important because they may broaden efficacy and strengthen the scientific rationale for clinical development. The company also seeks external funding and partnership opportunities to extend runway and reduce the capital burden of drug development.
The company’s value creation depends on generating clinical proof-of-concept for its most advanced synthetic lethality programs.
Combination regimens may improve efficacy and differentiate the assets in competitive oncology markets.
Earlier programs provide future pipeline depth and reduce dependence on a small number of candidates.
As a clinical-stage biotech with no product revenue, external capital is essential to fund development and extend runway.
Geography
Aprea is headquartered in Doylestown, Pennsylvania, and reports in U.S. dollars, but it also operates through its Swedish subsidiary Aprea AB. The company’s historical roots are in Sweden, while its corporate structure and capital markets presence are now centered in the United States. Its development work is global in nature because oncology R&D depends on external CROs, contract manufacturers, and clinical sites rather than a large owned manufacturing footprint. Geography matters mainly through foreign-currency exposure, cross-border operations, and the location of scientific talent and development infrastructure.
Risks
Aprea faces the typical risks of a clinical-stage biotech: its programs may fail in preclinical or clinical testing, and even promising science may not translate into approvable or commercially viable drugs. The company has incurred significant losses since inception and expects to continue losing money, so its ability to fund operations depends on future capital raises, grants, or partnerships. Because it has no product sales, any delay in development or financing can quickly pressure liquidity and increase dilution risk. Additional risks include Nasdaq continued listing compliance, dependence on third-party manufacturers and regulators, and foreign-currency exposure from its Swedish subsidiary.
- Need for additional capitalImpact: HighLikelihood: High
The company has incurred significant losses and has no commercial product revenue, so it must raise funds to continue development.
Exposure: Corporate runway and dilution risk
- Clinical development failureImpact: HighLikelihood: High
Drug candidates may not demonstrate sufficient safety, efficacy, or biomarker-driven benefit to advance.
Exposure - Nasdaq continued listing complianceImpact: HighLikelihood: Medium
Failure to meet listing requirements could lead to delisting and reduce liquidity and financing flexibility.
Exposure: Public equity market access
- Manufacturing and supply-chain dependenceImpact: MediumLikelihood: Medium
The company relies on contract manufacturers for APIs and drug product, which can create quality, capacity, and timing risks.
Exposure: Clinical supply and future commercial readiness
- Foreign exchange volatilityImpact: Low
Operations through Aprea AB create translation and remeasurement effects in consolidated U.S. dollar reporting.
Exposure: Swedish subsidiary balances and expenses
Accounting
Judgemental itemsClinical and preclinical vendors are often billed after services are performed, so management must estimate unpaid costs at period end.
Impact: Can materially affect quarterly R&D expense and net loss
Aprea AB is a foreign subsidiary with local-currency functional accounting, creating translation gains and losses in consolidation.
Impact: Affects other comprehensive loss and reported earnings volatility
The company has concluded it is more likely than not that deferred tax assets will not be realized in the future.
Impact: Prevents recognition of tax benefits that would otherwise reduce losses
Any non-product revenue depends on grant terms and milestone achievement, which can create uneven recognition patterns.
Impact: Can cause period-to-period volatility in other income
Similar listed companies
Publicly listed companies with a comparable business focus.
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
Kymera Therapeutics, Inc.
KYMR · Biological Products, (No Diagnostic Substances)
Aura Biosciences, Inc.
AURA · Biological Products, (No Diagnostic Substances)
Azitra, Inc.
AZTR · Pharmaceutical Preparations
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Tyra Biosciences, Inc.
TYRA · Pharmaceutical Preparations
Last updated: 24/09/2026